Key Facts GPs Should Know About GLP-1 Analogs
Family Medicine Initiative
APRIL 9, 2024
4 Chronic Kidney Disease The FLOW trial randomized 3,534 patients with chronic kidney disease and type 2 diabetes and started treating them with s.c. Both the FDA and EMA recommend that doctors monitor patients with diabetic retinopathy who are undergoing semaglutide treatment closely. semaglutide 1.0 mg or placebo in 2019.
Let's personalize your content